Literature DB >> 11986290

Helicobacter pylori seroprevalence in asymptomatic pregnant women in France.

N Kalach1, J Desramé, C Bonnet, P Commegeille, D Couturier, S Chaussade, P Hance, C Dupont, J Raymond.   

Abstract

The purpose of our study was to evaluate the incidence of Helicobacter pylori seropositivity in two different populations of asymptomatic pregnant women from different geographic origins during two separate time periods. A retrospective study of consecutive sera obtained from 169 and 302 asymptomatic pregnant women in 1990 and 1999, respectively, was carried out. The global H. pylori seroprevalences for 1990 and 1999 were 21.3 and 21.5% (where P is nonsignificant), respectively. For both periods the H. pylori seroprevalences were significantly higher in non-French pregnant women (66.6 and 50.6%) than in French pregnant women (18.7 and 11.2%) (P = 0.01 and 0.001, respectively). H. pylori seroprevalence in French pregnant women decreased significantly from the first period (18.7%) to the second one (11.2%) (P = 0.03).

Entities:  

Mesh:

Year:  2002        PMID: 11986290      PMCID: PMC119970          DOI: 10.1128/cdli.9.3.736-737.2002

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  6 in total

1.  Seroepidemiological study of Helicobacter pylori infection in infancy.

Authors:  M Ashorn; A Miettinen; T Ruuska; P Laippala; M Mäki
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-03       Impact factor: 5.747

2.  Helicobacter pylori seropositivity in patients with hyperemesis gravidarum.

Authors:  I Koçak; Y Akcan; C Ustün; C Demirel; L Cengiz; F F Yanik
Journal:  Int J Gynaecol Obstet       Date:  1999-09       Impact factor: 3.561

3.  Decreasing prevalence of helicobacter antibodies in Finland, with reference to the decreasing incidence of gastric cancer.

Authors:  L Rehnberg-Laiho; H Rautelin; P Koskela; S Sarna; E Pukkala; A Aromaa; P Knekt; T U Kosunen
Journal:  Epidemiol Infect       Date:  2001-02       Impact factor: 2.451

4.  Seroprevalence of Helicobacter pylori among Egyptian newborns and their mothers: a preliminary report.

Authors:  S Bassily; R W Frenck; E W Mohareb; T Wierzba; S Savarino; E Hall; A Kotkat; A Naficy; K C Hyams; J Clemens
Journal:  Am J Trop Med Hyg       Date:  1999-07       Impact factor: 2.345

5.  Helicobacter pylori acquisition in infancy after decline of maternal passive immunity.

Authors:  B D Gold; B Khanna; L M Huang; C Y Lee; N Banatvala
Journal:  Pediatr Res       Date:  1997-05       Impact factor: 3.756

6.  The prevalence of Helicobacter pylori positivity in a symptom-free population, aged 1 to 40 years.

Authors:  U Blecker; S Lanciers; B Hauser; Y Vandenplas
Journal:  J Clin Epidemiol       Date:  1994-10       Impact factor: 6.437

  6 in total
  5 in total

1.  Effect of Helicobacter pylori eradication therapy in iron deficiency anaemia of pregnancy - a pilot study.

Authors:  Ria Malik; Kiran Guleria; Iqbal Kaur; Meera Sikka; Gita Radhakrishnan
Journal:  Indian J Med Res       Date:  2011-08       Impact factor: 2.375

2.  Helicobacter pylori infection and related factors among pregnant women at Debre Tabor General Hospital, Northwest Ethiopia, 2021: Anemia highly related with H. pylori.

Authors:  Hiwot Yisak; Debaka Belete; Yeserk Mahtsentu
Journal:  Womens Health (Lond)       Date:  2022 Jan-Dec

3.  Seroepidemiology of helicobacter pylori infection in pregnant women in rural durango, Mexico.

Authors:  Cosme Alvarado-Esquivel
Journal:  Int J Biomed Sci       Date:  2013-12

4.  Burden of Helicobacter pylori Infections and Associated Risk Factors among Women of Child Bearing Age in Addis Ababa, Ethiopia.

Authors:  Kumera Terfa Kitila; Lemi Mosisa Sori; Daniel Melese Desalegn; Kassu Desta Tullu
Journal:  Int J Chronic Dis       Date:  2018-11-12

5.  Helicobacter pylori infection in pregnant women in four districts of Uganda: role of geographic location, education and water sources.

Authors:  Rhona Kezabu Baingana; John Kiboko Enyaru; Lena Davidsson
Journal:  BMC Public Health       Date:  2014-09-04       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.